156 related articles for article (PubMed ID: 37744269)
21. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.
Xie Q; Yang Z; Huang X; Zhang Z; Li J; Ju J; Zhang H; Ma J
J Hematol Oncol; 2019 Jun; 12(1):60. PubMed ID: 31186039
[TBL] [Abstract][Full Text] [Related]
22. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
23. Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells.
Kong Y; Qu F; Yuan X; Yan X; Yu W
Medicine (Baltimore); 2020 Apr; 99(17):e19822. PubMed ID: 32332626
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
[TBL] [Abstract][Full Text] [Related]
25. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
26. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
27. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
28. COL8A1 enhances the invasion/metastasis in MDA-MB-231 cells via the induction of IL1B and MMP1 expression.
Sagara A; Miura S; Kobinata A; Naganawa R; Yaginuma S; Saito S; Saito R; Kominato H; Yumoto T; Sato F
Biochem Biophys Res Commun; 2023 Jan; 642():145-153. PubMed ID: 36577251
[TBL] [Abstract][Full Text] [Related]
29. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
30. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer effect of a phytochemical compound - 7R-acetylmelodorinol - against triple-negative breast cancer cells.
Thepmalee C; Sawasdee N; Jenkham P; Thephinlap C; Khoothiam K; Suwannasom N; Chokchaisiri R; Panya A; Yenchitsomanus PT
Biomed Pharmacother; 2023 Oct; 166():115286. PubMed ID: 37573655
[TBL] [Abstract][Full Text] [Related]
32. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis.
Kashyap A; Umar SM; Dev J R A; Mathur SR; Gogia A; Batra A; Deo SVS; Prasad CP
J Cell Biochem; 2023 Sep; 124(9):1259-1272. PubMed ID: 37450687
[TBL] [Abstract][Full Text] [Related]
33. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Zhu Y; Tao Z; Chen Y; Lin S; Zhu M; Ji W; Liu X; Li T; Hu X
Breast Cancer Res Treat; 2022 May; 193(1):65-81. PubMed ID: 35254603
[TBL] [Abstract][Full Text] [Related]
34. The Fluoro-Thiazolylhydrazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction.
Zhang J; Dai J; Zheng Q; Guo S; Yu Y; Hu W; Gao Y; Shi D
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033205
[TBL] [Abstract][Full Text] [Related]
35. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
[TBL] [Abstract][Full Text] [Related]
36. MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Tumour Biol; 2016 Apr; 37(4):4991-9. PubMed ID: 26537583
[TBL] [Abstract][Full Text] [Related]
37. A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis.
Zhao P; Song H; Gao F; Chen L; Qiu J; Jin J; Pan C; Tang Y; Chen M; Pan Y; Li Y; Huang L; Yang J; Hao X
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110625
[TBL] [Abstract][Full Text] [Related]
38. CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.
Kim ES; Nam SM; Song HK; Lee S; Kim K; Lim HK; Lee H; Kang KT; Kwon YJ; Chun YJ; Park SY; Jung J; Moon A
Oncogene; 2021 May; 40(18):3245-3259. PubMed ID: 33833397
[TBL] [Abstract][Full Text] [Related]
39. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
40. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
